ストックスクリーナーアプリを入手
1.68
1.18%
-0.02
アフターアワーズ：
1.66
-0.02
-1.19%
前日終値:
$1.70
開ける：
$1.68
24時間の取引高:
769.21K
Relative Volume:
0.63
時価総額：
$130.37M
収益：
$257.24M
当期純損益:
$-237.89M
株価収益率:
-0.6462
EPS:
-2.6
ネットキャッシュフロー:
$-175.17M
1週間 パフォーマンス:
+1.82%
1か月 パフォーマンス:
+2.44%
6か月 パフォーマンス:
+63.11%
1年 パフォーマンス:
+125.50%
1日の値動き範囲:
$1.65
$1.71
1週間の範囲:
$1.59
$1.805
52週間の値動き範囲:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
名前
Coherus Oncology Inc
セクター
電話
(650) 649-3530
住所
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.68 | 197.59M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | アップグレード | Maxim Group | Hold → Buy |
| 2024-08-16 | ダウングレード | UBS | Buy → Neutral |
| 2023-11-17 | 開始されました | Robert W. Baird | Outperform |
| 2023-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-07-24 | 開始されました | Citigroup | Buy |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2023-03-28 | アップグレード | UBS | Neutral → Buy |
| 2022-06-14 | 開始されました | UBS | Neutral |
| 2022-03-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 開始されました | BofA Securities | Neutral |
| 2020-04-17 | 開始されました | SunTrust | Buy |
| 2019-08-13 | 開始されました | Mizuho | Buy |
| 2019-08-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-02 | 繰り返されました | Maxim Group | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-07 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-09 | 繰り返されました | Maxim Group | Buy |
| 2017-08-08 | 繰り返されました | JP Morgan | Overweight |
| 2017-06-13 | 繰り返されました | Maxim Group | Buy |
| 2017-05-05 | 開始されました | BMO Capital Markets | Outperform |
| 2016-10-19 | 開始されました | Robert W. Baird | Outperform |
| 2016-09-07 | 開始されました | Maxim Group | Buy |
| 2016-07-27 | 開始されました | Citigroup | Buy |
| 2016-01-20 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Coherus Oncology Inc (CHRS) 最新ニュース
Coherus Oncology's (NASDAQ:CHRS) investors will be pleased with their solid 132% return over the last year - Yahoo Finance
Can Coherus Oncology Inc. (8C5) stock retain market dominanceMarket Activity Report & Long-Term Safe Investment Plans - newser.com
Will Coherus BioSciences Inc. stock recover faster than marketBuy Signal & Breakout Confirmation Trade Signals - newser.com
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Coherus Oncology (NASDAQ: CHRS) schedules Nov. 6 results release and 5 p.m. ET call - Stock Titan
CapEx per share of Coherus Oncology, Inc. – DUS:8C5 - TradingView
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Coherus Oncology (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
How Coherus Oncology Inc. (8C5) stock performs during market turbulenceLayoff News & Scalable Portfolio Growth Methods - newser.com
Despite shrinking by US$22m in the past week, Coherus Oncology (NASDAQ:CHRS) shareholders are still up 122% over 1 year - simplywall.st
Aug Ideas: How Coherus Oncology Inc. (8C5) stock performs during market turbulenceJuly 2025 Retail & Consistent Profit Trading Strategies - Fundação Cultural do Pará
Coherus Oncology (NASDAQ:CHRS) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
Will Coherus BioSciences Inc. stock deliver better than expected guidanceLayoff News & Real-Time Volume Surge Alerts - newser.com
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
What analysts say about Coherus Oncology Inc 8C5 stockStock Buy Signals & Maximum Profit Growth - earlytimes.in
Will Coherus Oncology Inc. (8C5) stock benefit from infrastructure billPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Will Coherus Oncology Inc. (8C5) stock outperform value peersBuy Signal & Community Verified Trade Alerts - newser.com
Coherus (NASDAQ: CHRS) to present at UBS, Jefferies, Baird; 30-day replays - Stock Titan
Lobbying Update: $80,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
What dividend safety rating applies to Coherus Oncology Inc. (8C5) stock2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Why Coherus Oncology Inc. (8C5) stock is trending on social media2025 Geopolitical Influence & Long Hold Capital Preservation Tips - newser.com
Guidance Update: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Momentum & Long-Term Growth Portfolio Plans - nchmf.gov.vn
Stock Market Recap: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Trends & Technical Pattern Recognition Alerts - Trung tâm Dự báo KTTV quốc gia
CHRS (Coherus Oncology) EBITDA Margin % : -405.39% (As of Jun. 2025) - GuruFocus
Coherus Oncology, Inc.Common Stock (Nasdaq:CHRS) Stock Quote | Oklahoma City NewsThe Oklahoman - FinancialContent
How Coherus Oncology Inc. (8C5) stock reacts to monetary easing2025 Dividend Review & Real-Time Market Trend Scan - newser.com
What technical patterns form on Coherus Oncology Inc. (8C5) stock chartsMarket Sentiment Review & Weekly Return Optimization Plans - newser.com
Revenue per share of Coherus Oncology, Inc. – MUN:8C5 - TradingView
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - inkl
How strong dollar benefits Coherus Oncology Inc. (8C5) stockJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Published on: 2025-10-06 04:13:27 - newser.com
Published on: 2025-10-05 03:27:37 - newser.com
Coherus Oncology Inc (CHRS) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):